Vnitr Lek 2021, 67(4):218-222 | DOI: 10.36290/vnl.2021.056

Importance and efficiency of blood pressure control not only in type 2 diabetes patients

Veronika Vejtasová1, Jana Urbanová2, Ludmila Brunerová2, Michala Lustigová3, 4, Michael Jenšovský5, Barbora Prýmková5, Sabina Pálová5, Jan Brož5
1 Kardiologická klinika 2. LF UK a FN v Motole, Praha
2 Interní klinika 3. LF UK a FNKV, Praha
3 Státní zdravotní ústav, Praha
4 Přírodovědecká fakulta UK, Praha
5 Interní klinika 2. LF UK a FN v Motole, Praha

Arterial hypertension is one of the most frequent comorbidities of patients with type 2 diabetes, the rates are approximately three times higher among diabetics than in general population. The presence of both diseases increases the cardiovascular risk of the patients two to three times. Therefore, it is essential to control the blood pressure values vigorously down to 130/80 mmHg as recommended in guidelines of the Czech Hypertension Society. According to EHES Study data, the blood pressure control is not sufficient in Czech diabetic population. The target values are reached in only 29 % of diabetics. A well organized system of care, intensive antihypertensive treatment, self-monitoring of patients or appointment reminder system can be used to improve blood pressure control.

Keywords: arterial hypertension, type 2 diabetes, blood pressure control, masked hypertension.

Published: June 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vejtasová V, Urbanová J, Brunerová L, Lustigová M, Jenšovský M, Prýmková B, et al.. Importance and efficiency of blood pressure control not only in type 2 diabetes patients. Vnitr Lek. 2021;67(4):218-222. doi: 10.36290/vnl.2021.056.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002; 360(9349): 1903-1913. Go to original source... Go to PubMed...
    2. Chow CK, Teo KK, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. Jama. 2013; 310(9): 959-968. Go to original source... Go to PubMed...
    3. Čapková N, Lustigová M, Kratěnová J et al. Zdravotní stav české populace: výsledky studie EHES 2014. Praha: Státní zdravotní ústav, 2016. ISBN 978-80-7071-356-3.
    4. Cífková R, Bruthans J, Wohlfahrt P et al. The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech post-MONICA study). Cor et Vasa [online]. 2020; 62(1): 6-16 [cit. 2020-03-27]. DOI: 10.33678/cor.2020.010. ISSN 00108650. Dostupné z: http://e-coretvasa.cz/doi/10.33678/cor.2020.010.html Go to original source...
    5. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension [online]. 2013; 31(7): 1281-1357 [cit. 2020-03-26]. DOI: 10.1097/01.hjh.0000431740.32696.cc. ISSN 0263-6352. Dostupné z: Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension [online]. 2013; 31(7): 1281-1357 [cit. 2020-03-26]. DOI: 10.1097/01.hjh.0000431740.32696.cc. ISSN 0263-6352. Go to original source... Go to PubMed...
    6. Filipovský J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék, 2012; 58(10): 785-801. Go to PubMed...
    7. Svačina Š. Hypertenze při obezitě a diabetu. Triton, 2007.
    8. Rosolová H. Hypertenze a diabetes - maligní kardiometabolická kombinace. AtheroRev. 2019; 4(2): 87-90.
    9. Prevalence diabetu mellitu: Prevalence diabetu mellitu v roce 2016 v ČR absolutně a na 1 000 obyvatel [online]. In: ÚZIS ČR, Výkaz ambulantní péče A004, 2017 [cit. 2020-03-29]. Dostupné z: https://reporting.uzis.cz/cr/index.php?pg=statisticke-vystupy--morbidita--intervalova-prevalence-dle-diagnoz--prevalence-diabetu-mellitu.
    10. Chen G et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension, 2011; 57(5): 891-897. Go to original source... Go to PubMed...
    11. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. European heart journal, 2007; 28(24): 3059-3066. Go to original source... Go to PubMed...
    12. Libianto R et al. Pathophysiological links between diabetes and blood pressure. Canadian Journal of Cardiology, 2018; 34(5): 585-594. Go to original source... Go to PubMed...
    13. Alberti KG et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; nationalheart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation, 2009; 120(16): 1640-1645. Go to original source... Go to PubMed...
    14. Conroy RM et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European heart journal, 2003; 24(11): 987-1003. Go to original source... Go to PubMed...
    15. Widimský J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Hypertenze & kardiovaskulární prevence, 2018; 7: 2-22.
    16. Emdin CA et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. Jama, 2015; 313(6): 603-615. Go to original source... Go to PubMed...
    17. Cífková R. Kardiovaskulární riziko u žen. Kapitoly z kardiologie [online]. 2019; 7(1): 14-17 [cit. 2020-03-29]. Dostupné z: https://www.tribune.cz/clanek/35787-kardiovaskularni-riziko-u-zen
    18. Rosolova H, Pelikanova T, Moťovská Z. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. Summary of the document prepared by the Czech Society of cardiology. Cor Vasa. 2014; 56: e190-205. Dostupné z: https://academic.oup.com/eurheartj/article/34/39/3035/503593?login=true. Go to original source...
    19. Williams B et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European heart journal, 2018; 39(33): 3021-3104. Go to original source... Go to PubMed...
    20. Petrie JR et al. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. Journal of hypertension, 2016; 34(6): 1140. Go to original source... Go to PubMed...
    21. Rückert IM et al. Blood pressure control has improved in people with and without type 2 diabetes but remains suboptimal: a longitudinal study based on the German DIAB-CORE consortium. PloSone, 2015; 10(7): e0133493. Go to original source... Go to PubMed...
    22. Charvát J. Jaký význam má fenomén "maskované" hypertenze u nemocných s diabetes mellitus 2. typu léčených pro setrvalou hypertenzi? VnitrLek, 2016; 62(3): 215-217.
    23. Hanninem MR, Niiranen TJ, Puukka PJ et al. Determinants of Masked hypertension in the general population: the Finn-Home study. J Hypertension 2011; 29(10): 1880-1888. Go to original source... Go to PubMed...
    24. Franklin SS et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension, 2013; 61(5): 964-971. Go to original source... Go to PubMed...
    25. Accord Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New England Journal of Medicine, 2010; 362(17): 1575-1585. Go to original source... Go to PubMed...
    26. Hunsicker LG et al. Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney International, 2004(66): 99-101. Go to original source... Go to PubMed...
    27. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet, 2000; 355(9200): 253-259. Go to original source... Go to PubMed...
    28. Mann FE et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet, 2008; 372(9638): 547-553. Go to original source... Go to PubMed...
    29. Jamerson K et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Pressure, 2007; 16(2): 80-86. Go to original source... Go to PubMed...
    30. Williams B et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. The Lancet, 2015; 386(10008): 2059-2068. Go to original source... Go to PubMed...
    31. Meredith PA, Reid JL. Efficacy and Tolerability of Long-Term Rilmenidine Treatment in Hypertensive Diabetic Patients. American Journal of Cardiovascular Drugs, 2004; 4(3): 195-200. Go to original source... Go to PubMed...
    32. Zinman B et al. EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke, 2017; 48: 1218-1225. Go to original source... Go to PubMed...
    33. Neal B et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 2017; 377(7): 644-657. Go to original source... Go to PubMed...
    34. Khatib R, Schwalm JD, Yusuf S et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoSOne. 2014; 9(1): e84238. Dostupné z DOI: 10.1371/journal.pone.0084238. Go to original source... Go to PubMed...
    35. Fixed-dose triple-combination treatments in the management of hypertension. Manag Care. 2013; 22(12): 45-55.
    36. Porter AK, Taylor SR, Yabut AH et al. Impact of a pill box clinic to Improve systolic blood pressure in veterans with uncontrolled hypertension taking 3 or more antihypertensive medications. Journal of Managed Care Pharmacy. 2014; 20(9): 905-911. Go to original source... Go to PubMed...
    37. Gandapur Y, Kianoush S, Kelli HM et al. The role of mHealth for improving medication adherence in patiens with cardiovascular disease: a systematic review. Eur Heart J Qual Care Clin Outcomes. 2016; 2(4): 237-244. Go to original source... Go to PubMed...
    38. Ogedegbe G. Barriers to optimal hypertension control. The Journal of Clinical Hypertension, 2008; 10(8): 644-646. Go to original source... Go to PubMed...
    39. Filippi A, Degli Esposti L, Buda S et al. Why is my hypertensive patient still not controlled? High Blood Press Cardiovasc Prev. 2015; 22(1): 69-72. Dostupné z: doi: 10.1007/s40292-014-0075-y. Go to original source... Go to PubMed...
    40. Davis DA et al. Changing physician performance: a systematic review of the effect of continuing medical education strategies. Jama, 1995; 274(9): 700-705. Go to original source... Go to PubMed...
    41. Phillips LS et al. Clinical inertia. Annals of internal medicine, 2001; 135(9): 825-834. Go to original source... Go to PubMed...
    42. McDonald CJ et al. Reminders to physicians from an introspective komputer medical record: a two-year randomized trial. Annals of internal medicine, 1984; 100(1): 130-138. Go to original source... Go to PubMed...
    43. Glynn LG et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane database of systematic reviews, 2010, 3. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.